Regulation of 5-HT Receptor Binding as a Biochemical model for Pathological or Functional Changes in the CNS

  • Wolfgang Wesemann
  • Norbert Arold
  • Appletree Rodden
  • Nina Weiner


Chemically mediated neurotransmission and the transmitter-receptor interaction depend on the amount of transmitter molecules released as quantal units into the synaptic cleft [Del Castillo and Katz, 1955]. Aside from transmitter concentration also the quality and quantity of receptor molecules will affect the transmission process. Though biochemical in vitro studies are restricted to the characterization of ligand-receptor binding which can supply only limited information about the possible physiological response, the measurement of binding kinetics has proved to be a suitable tool for describing central dysfunctions on the molecular level. After cerebral insult a significant decrease in 5-HT binding was observed in membranes isolated from the infarct region as compared with fractions obtained from intact regions or from control postmortem brain [Weiner et al., 1979]. The possibility that changes in ligand-receptor interaction reflect merely generalized necrosis or postmortem changes seems unlikely in the light of studies on 5-HT binding in Huntington’s chorea [Enna et al., 1976].


Tourette Syndrome Receptor Sensitivity Crude Membrane Crude Membrane Fraction Cerebral Insult 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bernheimer, H., and Hornykiewicz, O. (1973). Brain amines in Huntington’s chorea. In Advances in Neurology, Vol. 1 (eds. A. Barbeau, T.N. Chase, and G.W. Paulson), pp. 525–531, Raven Press, New York.Google Scholar
  2. Berlett, H.H., Bull, C., Himwich, H.E., Kohl, H., Matsumoto, K., Pscheidt, G.R., Spaide, J., Tourlentes, T.T., and Valverde, J.M. (1964). Endogenous metabolic factor in schizophrenic behavior. Sci., 144, 311–313.CrossRefGoogle Scholar
  3. Birkmayer, W. (1969). Der α-Methyl-p-tyrosin-Effekt bei extrapyramidalen Erkrankungen. Wien. Klin. Wochenschr., 81, 10–12.Google Scholar
  4. Brune, G.G., and Himwich, H.E. (1963). Biogenic amines and behavior in schizophrenic patients. Rec. Adv. Biol. Psychiat., 5, 144–160.Google Scholar
  5. Del Castillo, J. and Katz, B. (1955). On the localization of acetylcholine receptors. J. Physiol. (Lond.), 128, 157–181.CrossRefGoogle Scholar
  6. Enna, S.J., Bird, E.D., Bennett, J.P., Jr., Bylund, D.B., Yamamura, H.I., Iversen, L.L., and Snyder, S.H. (1976). Huntington’s chorea. Changes in neurotransmitter receptors in the brain. New England J. Med., 294, 1305–1309.CrossRefGoogle Scholar
  7. Enna, S.J., Bennett, J.P., Jr., Bylund, D.B., Creese, I., Burt, D.R., Charness, M.E., Yamamura, H.I., Simantov, R., and Snyder, S.H. (1977). Neurotransmitter receptor binding: regional distribution in human brain. J. Neurochem., 28, 233–236.CrossRefGoogle Scholar
  8. Friedhoff, A.J., and Alpert, M. (1978). Receptor sensitivity modification as a potential treatment. In Psychopharmacology: a generation of progress (eds. M.A. Lipton, A. DiMascio, and K.F. Killam), pp. 797–801, Raven Press, New York.Google Scholar
  9. Friedman, R.N. (1979). Tryptamine induced alterations of acetylcholine release at a neuromuscular juntion. Soc. Neurosci. Abstr. 5, 480.Google Scholar
  10. Friend, D.G., Bell, W.R., and Kline, N.S. (1965). The action of L-dihydroxyphenylalanine in patients receiving nialamide. Clin. Pharmacol. Ther., 6, 362–366.Google Scholar
  11. Jones, Rosogo and Boulion, A.A. (1980). Interactions between p-tyramine, m-tyramine, or β-phenylethylamine and dopamine on single neurons in the cortex and caudate nucleus of the rat. Can. J. Physiol. Pharmacol., 58, 222–227.CrossRefGoogle Scholar
  12. Leslie, F.M., Dunlap, C.E., III, and Cox, B.M. (1980). Ascorbate decreases ligand binding to neurotransmitter receptors. J. Neurochem., 34, 219–221.CrossRefGoogle Scholar
  13. Perry, Th.L., Wright, J.M., Hansen, S., and MacLeod, P.M. (1979). Isoniazid therapy for Huntington’s disease. In Advances in Neurology, Vol. 23 (eds. T.N. Chase, N.S. Wexler, and A. Barbeau), pp. 785–796, Raven Press, New York.Google Scholar
  14. Savage, D.D., Mendels, J., and Frazer, A. (1980). Monoamine oxidase inhibitors and serotonin uptake inhibitors: differentiated effects on [3H]serotonin binding sites in rat brain. J. Pharmacol. Exp. Ther., 212, 259–263.Google Scholar
  15. Schaefer, A., Komlos, M., and Seregi, A. (1975). Lipid peroxidation as the cause of the ascorbic acid induced decrease of adenosine triphosphatase activities of rat brain microsomes and its inhibition by biogenic amines and psychotropic drugs. Biochem. Pharmacol., 24, 1781–1786.CrossRefGoogle Scholar
  16. Snyder, S.H. and Bennett, J.P., Jr., (1975). Biochemical identification of the postsynaptic serotonin receptor in mammalian brain. In Modern pharmacology — toxicology, Vol. 3: Pre- and postsynaptic receptors (eds. E. Usdin and W.E. Bunney, Jr) pp. 191–206, Dekker, New York.Google Scholar
  17. Stahl, W.L. and Swanson, P.D. (1974). Biochemical abnormalities in Huntington’s chorea brains. Neurology, 24, 813–819.CrossRefGoogle Scholar
  18. Weiner, N., Martin, C., Wesemann, W., and Riederer, P. (1979). Effect of post-mortem storage on synaptic 5-HT binding and uptake in mammalian brain. J.Neural Transm., 46, 253–262.CrossRefGoogle Scholar
  19. Wesemann, W. (1969). Isolation of 5-hydroxytryptamine containing vesicles and of synaptic membranes from rat brain. FEBS Letters, 3, 80–84.CrossRefGoogle Scholar

Copyright information

© The Contributors 1981

Authors and Affiliations

  • Wolfgang Wesemann
    • 1
  • Norbert Arold
    • 1
  • Appletree Rodden
    • 1
  • Nina Weiner
    • 1
  1. 1.Abteilung für Neurochemie, Physiologisch-Chemisches Institut IIPhilipps-UniversitätMarburg/LahnWest Germany

Personalised recommendations